Ironwood Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Ironwood Pharmaceuticals (NASDAQ: IRWD) announced that CEO Tom McCourt will present at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 7:30 a.m. ET. The presentation will be held virtually, and investors can access the live audio webcast via the company’s website. A replay will be available for 14 days post-conference. Ironwood is focused on advancing treatments for gastrointestinal diseases, including its flagship product LINZESS® for IBS-C and CIC.

BOSTON--(BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today announced that Tom McCourt, CEO, will present at the 40^th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 7:30 a.m. ET.

The event is being held virtually and a live audio webcast of Ironwood’s presentation will be accessible through the Investors section of the company’s website at www.ironwoodpharma.com. To access the webcast, please log on to the Ironwood website approximately 15 minutes prior to the start time to ensure adequate time for any software downloads that may be required. A replay of the webcast will be available on Ironwood’s website for 14 days following the conference.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals (Nasdaq: IRWD) is a leading gastrointestinal (GI) healthcare company on a mission to advance the treatment of GI diseases and redefine the standard of care for GI patients. We are pioneers in the development of LINZESS® (linaclotide), the U.S. branded prescription market leader for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). Under the guidance of our seasoned industry leaders, we continue to build upon our history of GI innovation and challenge what has been done before to shape what the future holds. We keep patients at the heart of our R&D and commercialization efforts to reduce the burden of GI diseases and address significant unmet needs.

Founded in 1998, Ironwood Pharmaceuticals is headquartered in Boston, Massachusetts.

We routinely post information that may be important to investors on our website at www.ironwoodpharma.com. In addition, follow us on Twitter and on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220105005023/en/

Investors:

Matt Roache, 617-621-8395

Director, Investor Relations

mroache@ironwoodpharma.com

Source: Ironwood Pharmaceuticals, Inc.

FAQ

When will Ironwood Pharmaceuticals present at the J.P. Morgan Healthcare Conference?

Ironwood Pharmaceuticals will present on January 12, 2022, at 7:30 a.m. ET.

How can I access the Ironwood Pharmaceuticals conference presentation?

The presentation can be accessed through the Investors section of Ironwood's website.

What is Ironwood Pharmaceuticals known for?

Ironwood Pharmaceuticals is known for its focus on gastrointestinal diseases and its leading product, LINZESS®.

Where is Ironwood Pharmaceuticals headquartered?

Ironwood Pharmaceuticals is headquartered in Boston, Massachusetts.

Is there a replay available for the Ironwood Pharmaceuticals conference presentation?

Yes, a replay of the presentation will be available on Ironwood's website for 14 days following the conference.